ty -jour t1-对第一线和可注射药物的抵抗力对MDR -TB JF中的治疗结果的影响 - 欧洲呼吸杂志-Hwang，S。S。Au -Kim，H -R。Au -Kim，H。J. Au -Kim，M。J. Au -Lee -S.M.Au -Yoo，C -G。au -kim，Y。W. au -han，S。K. au -shim，y -s。Au -Yim，J -J。Y1-2009/03/01 UR -http：//www.qdcxjkg.com/content/33/3/3/581.abstract N2-最近，据报道，对其他一线和可注射药物的抵抗是对额外的一线和可注射药物的抵抗力是独立的风险因素多药（MDR）结核病（TB）患者的不良结局。本研究的目的是在没有HIV感染的MDR-TB患者中确认这些观察结果。1996年1月至2005年12月，包括在韩国的三级转诊医院接受治疗的MDR-TB患者。计算了对每种药物的耐药性和使用简单或多重逻辑回归的药物组合的不良治疗结果的未经调整和调整后的优势比。 None of the resistance to additional first-line or injectable drugs was associated with higher odds for adverse treatment outcome in 155 MDR but nonextensively drug-resistant (non-XDR) TB patients. However, streptomycin resistance was associated with 12 times the odds for adverse treatment outcome in 42 extensively drug-resistant (XDR) TB patients. Neither combinations of first-line drugs nor those of injectable drugs were associated with increased odds for adverse treatment outcomes in non-XDR MDR-TB patients or XDR-TB patients. Only streptomycin resistance among the first-line or injectable drugs was associated with adverse treatment outcomes in extensively drug-resistant tuberculosis patients without HIV infection. ER -